Health Care Select Sector SPDR Fund : XLV

XLV

Stock Data

$159.25

$1.84 (1.14%)

Asset Type

N/A

Exchange

N/A

Currency

N/A

Country

N/A

Sector

N/A

Industry

N/A

All XLV Articles

23 Articles

David Beren | Jul 9, 2026 at 12:18 PM EDT

Two Drugmakers Own 90% of the Obesity Boom. One Fund Owns Both for 0.59%

The Health Care Select Sector SPDR Fund (NYSEARCA:XLV) is the default healthcare allocation for millions of investors, and for good…

Omor Ibne Ehsan | Jul 7, 2026 at 2:45 PM EDT

Goldman’s Top Strategist Sees a Dangerous Amount of Leverage Piling Up

Ben Snider, Chief U.S. Equity Strategist at Goldman Sachs, went on CNBC to say something that should register with anyone…

Marc Guberti | Jun 21, 2026 at 4:17 PM EDT

The 2 Factors That Will Decide Whether XLV Finally Catches the S&P 500 in 2026

The Health Care Select Sector SPDR ETF (NYSEARCA:XLV) is having a frustrating year. The fund sits at $149, down about…

Joel South | Jun 13, 2026 at 9:30 AM EDT

3 Ridiculously Cheap Healthcare Stocks to Buy in June

Healthcare has spent 2026 on the sidelines while the rest of the market does the heavy lifting. The Health Care…

Thomas Richmond | Jun 7, 2026 at 9:30 AM EDT

Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech

After years of lagging the market, healthcare may be taking on a new role in investor portfolios. Speaking on CNBC,…

David Moadel | Jun 4, 2026 at 1:32 PM EDT

Humana Jumps 6%, UnitedHealth Climbs 5%, Cigna Rises 4% as Analysts Cheer Softer Medical Cost Trends

Health insurers are running higher in Thursday afternoon trading after a wave of bullish Wall Street analyst notes on the…

Tony Dong | May 20, 2026 at 8:30 AM EDT

When 2022 Tore Through the S&P 500, This Healthcare ETF Barely Flinched. Why Isn’t It in More Retirement Accounts?

2022 was a really weird year to be an investor. Even four years later, I still remember what happened. A…

Omor Ibne Ehsan | May 19, 2026 at 4:19 PM EDT

Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?

The iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) is the rare fund that has spent the past year being publicly threatened by…

Austin Smith | Apr 29, 2026 at 7:23 AM EDT

Healthcare’s Defensive Promise Crumbles: XLV Down 7% While SPY Rises 5% in 2026

Healthcare is supposed to be the place you hide. It is the fourth-largest slice of U.S. GDP at 8.9% in…

Michael Williams | Mar 26, 2026 at 2:32 PM EDT

VHT Lagged the Market by 57 Points Over 5 Years. Here Is Why Long-Term Investors Still Hold It

Healthcare spending doesn’t stop during recessions. That structural reality is the core argument for owning Vanguard Health Care ETF (NYSEARCA:VHT),…

Joel South | Mar 17, 2026 at 11:56 AM EDT

Why One Analyst Thinks Johnson & Johnson Reaches $280

Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) has been one of healthcare’s standout performers over the past year, with…

Tony Dong | Mar 9, 2026 at 9:33 AM EDT

The “Cockroach” Portfolio: Why This 5-ETF Strategy Is Every Retiree’s Best Defense Against a 2026 Recession

Talk of a recession is once again dominating the headlines. The latest job report has just been released, showing a…

Austin Smith | Feb 18, 2026 at 5:32 AM EST

XLV is A $41 Billion Defensive Healthcare Play That Looks Good Until You Compare To The S&P 500

Healthcare isn’t going anywhere. An aging population, chronic disease management, and breakthrough treatments ensure this sector remains essential regardless of…

Joey Frenette | Jan 29, 2026 at 12:16 PM EST

2 Hot Sector ETFs Worth Buying in 2026

Index investors and so-called Bogleheads (those who love the Vanguard ETFs) may not be all too fond of the sector…

Michael Williams | Jan 29, 2026 at 8:20 AM EST

PINK’s 58% Gains Since 2021 Come From Picking Winners, Not Owning Everything

Healthcare is supposed to be defensive. When tech stocks swing wildly and consumer spending wobbles, healthcare companies keep selling drugs,…

1 2

Health Care Select Sector SPDR Fund : XLV

XLV

$159.25

All XLV Articles

Two Drugmakers Own 90% of the Obesity Boom. One Fund Owns Both for 0.59%

Goldman’s Top Strategist Sees a Dangerous Amount of Leverage Piling Up

The 2 Factors That Will Decide Whether XLV Finally Catches the S&P 500 in 2026

3 Ridiculously Cheap Healthcare Stocks to Buy in June

Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech

Humana Jumps 6%, UnitedHealth Climbs 5%, Cigna Rises 4% as Analysts Cheer Softer Medical Cost Trends

When 2022 Tore Through the S&P 500, This Healthcare ETF Barely Flinched. Why Isn’t It in More Retirement Accounts?

Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?

Healthcare’s Defensive Promise Crumbles: XLV Down 7% While SPY Rises 5% in 2026

VHT Lagged the Market by 57 Points Over 5 Years. Here Is Why Long-Term Investors Still Hold It

Why One Analyst Thinks Johnson & Johnson Reaches $280

The “Cockroach” Portfolio: Why This 5-ETF Strategy Is Every Retiree’s Best Defense Against a 2026 Recession

XLV is A $41 Billion Defensive Healthcare Play That Looks Good Until You Compare To The S&P 500

2 Hot Sector ETFs Worth Buying in 2026

PINK’s 58% Gains Since 2021 Come From Picking Winners, Not Owning Everything

If I Could Only Own 1 ETF for the Rest of 2026, It Would Be This One

Ryanair CFO: Rival Airlines Could Fail This Winter; Industry Shakeout Could Lead to Pricing Power

The Divorce Settlement Mistake Costing Retirees Thousands

The Roth Conversion Window That Closes Faster Than Most 401(k) Savers Expect

If You Just Inherited an IRA, Read This

If I Could Only Own 1 ETF for the Rest of 2026, It Would Be This One

Ryanair CFO: Rival Airlines Could Fail This Winter; Industry Shakeout Could Lead to Pricing Power

Health Care Select Sector SPDR Fund : XLV

XLV

$159.25

All XLV Articles

Two Drugmakers Own 90% of the Obesity Boom. One Fund Owns Both for 0.59%

Goldman’s Top Strategist Sees a Dangerous Amount of Leverage Piling Up

The 2 Factors That Will Decide Whether XLV Finally Catches the S&P 500 in 2026

3 Ridiculously Cheap Healthcare Stocks to Buy in June

Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech

Humana Jumps 6%, UnitedHealth Climbs 5%, Cigna Rises 4% as Analysts Cheer Softer Medical Cost Trends

When 2022 Tore Through the S&P 500, This Healthcare ETF Barely Flinched. Why Isn’t It in More Retirement Accounts?

Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?

Healthcare’s Defensive Promise Crumbles: XLV Down 7% While SPY Rises 5% in 2026

VHT Lagged the Market by 57 Points Over 5 Years. Here Is Why Long-Term Investors Still Hold It

Why One Analyst Thinks Johnson & Johnson Reaches $280

The “Cockroach” Portfolio: Why This 5-ETF Strategy Is Every Retiree’s Best Defense Against a 2026 Recession

XLV is A $41 Billion Defensive Healthcare Play That Looks Good Until You Compare To The S&P 500

2 Hot Sector ETFs Worth Buying in 2026

PINK’s 58% Gains Since 2021 Come From Picking Winners, Not Owning Everything

If I Could Only Own 1 ETF for the Rest of 2026, It Would Be This One

Ryanair CFO: Rival Airlines Could Fail This Winter; Industry Shakeout Could Lead to Pricing Power

The Divorce Settlement Mistake Costing Retirees Thousands

Featured Reads

The Roth Conversion Window That Closes Faster Than Most 401(k) Savers Expect

If You Just Inherited an IRA, Read This